Household Air Pollution and Health: A Multi-country LPG Intervention Trial (HAPIN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02944682|
Recruitment Status : Recruiting
First Posted : October 26, 2016
Last Update Posted : May 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|Infant, Low Birth Weight||Other: Liquefied petroleum gas (LPG) cookstove||Not Applicable|
Globally, nearly 3 billion people rely on solid fuels for cooking and heating, the vast majority in low- and middle-income countries (LMICs). The resulting household air pollution (HAP) is the third leading risk factor in the 2010 global burden of disease, accounting for an estimated 4.3 million deaths annually, largely among women and young children. Previous interventions have provided cleaner biomass-based cookstoves, but have failed to reduce exposure to levels that produce meaningful health improvements. There have been no large-scale field trials with liquefied petroleum gas (LPG) cookstoves, likely the cleanest scalable intervention.
The aim of this study is to conduct a randomized controlled trial of LPG stove and fuel distribution in 3,200 households in four LMICs (India, Guatemala, Peru, and Rwanda) to deliver rigorous evidence regarding potential health benefits across the lifespan. Each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation), and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels, and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. In households with a second, non-pregnant older adult woman (aged 40 to <80 years) the researchers will also enroll and follow her during the 18-month follow-up period in order to assess cardiopulmonary, metabolic, and cancer outcomes. To optimize intervention use, the researchers will implement behavior change strategies. This study will assess cookstove use, conduct repeated personal exposure assessments to HAP (PM2.5, black carbon, carbon monoxide), and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage on all participants at multiple time points. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and blood pressure in the older adult woman. Secondary outcomes include preterm birth and development in the child, maternal blood pressure during pregnancy, and endothelial function, respiratory impairment, atherosclerosis, carcinogenic metabolites, and quality of life in the older adult woman.
This study will address the following specific aims: (1) using an intent-to-treat analysis, determine the effect of a randomized LPG stove and fuel intervention on health in four diverse LMIC populations using a common protocol; (2) determine the exposure-response relationships for HAP and health outcomes; and (3) determine relationships between LPG intervention and both targeted and exploratory biomarkers of exposure/health effects.
This study will provide evidence, including costs and implementation strategies, to inform national and global policies on scaling up LPG stoves among vulnerable populations. Ultimately, this will facilitate deeper policy-level discussions as well as identify requirements for initiating and sustaining HAP interventions globally.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||7200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Household Air Pollution and Health: A Multi-country LPG Intervention Trial|
|Actual Study Start Date :||April 16, 2018|
|Estimated Primary Completion Date :||August 2021|
|Estimated Study Completion Date :||August 2021|
Experimental: Liquefied petroleum gas cookstove
Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
Other: Liquefied petroleum gas (LPG) cookstove
The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
No Intervention: Control
Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
- Birth weight [ Time Frame: Up to 5 months (within 24 hours of birth, 3-5 months post randomization) ]Newborn weight will be assessed by a trained nurse or health worker at the <24-hour visit during the changing of newborn into pre-weighed clothing to keep the infant at least partially covered to prevent cold stress. Weight will measured to the nearest 10 g using a digital electronic scale. Calibration of scales and infantometers, using standard weight and height measures, will be done at the start of each measurement session.
- Incidence of Pneumonia [ Time Frame: Up to 12 months after birth ]The number of times that a child has pneumonia during the first one year of life will be assessed. Active surveillance for acute lower respiratory infections in infants will be conducted at home visits at 24 hours, and at 5 visits until the child reaches 12 months of age. Health workers will be trained to recognized influenza-like illness (cough or sore throat, and fever >38°C) and danger signs of pneumonia using Integrated Management of Childhood Illness (IMCI) definitions. Infants with severe acute lower respiratory infections (hypoxemia measured by portable pulse oximeter or with chest indrawing or stridor) will be referred for pulmonary ultrasound, and also referred to standard medical care.
- Length-for-age z-score [ Time Frame: 12 months after birth ]The primary outcome measured is linear growth failure, or stunting, at one year of age. Infant length will be assessed quarterly, until the child is 12 months old. Stunting will be assessed using height-for-age z-scores (HAZ) based on the 2006 World Health Organization (WHO) Child Growth Standards. Stunting is defined as HAZ <-2 standard deviations (SD) below the median z-score.
- Blood pressure [ Time Frame: Up to 18 months ]Blood pressure will be assessed in the older adult women in the intervention and control arms using automatic sphygmomanometers (OMRON M6 Comfort IT; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.
- Maternal blood pressure [ Time Frame: Up to 5 months ]Blood pressure will be assessed in the pregnant women in the intervention and control arms using automatic sphygmomanometers (OMRON M6 Comfort IT; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.
- Change in fetal growth [ Time Frame: Baseline, Gestation Week 24-28 and Gestation Week 32-36 ]Pregnant women will have ultrasounds at Baseline and during gestation weeks 24-28 and gestation weeks 32-36 to measure fetal growth. Abnormal fetal growth will be defined as an estimated fetal weight of less than the 10th percentile for gestational age based on the recently completed international standard for fetal growth (INTERGROWTH-21st) produced by the World Health Organization (WHO).
- Preterm birth [ Time Frame: Up to 5 months (within 24 hours of birth, 3-5 months post randomization) ]Preterm birth is defined as delivery of a living infant prior to 37 completed weeks of gestation.
- Change in child development [ Time Frame: 3 months of age to 12 months of age ]Child development will be assessed with the Caregiver Reported Early Childhood Development Instrument (CREDI). The CREDI is a population-level measure of early childhood development (ECD) for children from 0-3 years of age. The CREDI assesses 5 domains of child development: 1) motor development (fine and gross motor), 2) language development (expressive and receptive language), 3) cognitive development (executive function, problem solving and reasoning, and pre-academic knowledge), 4) socio-emotional development (emotional and behavioral self-regulation, emotional knowledge, and social competence), and 5) mental health (internalizing and externalizing behaviors). The CREDI long form has 117 items and the number of questions answered depends on the age of the child. Responses of "yes" are coded as 1 and "no" is coded as 0; certain items are reverse coded. Total raw scores increase by age (with developmental progression), and higher scores indicate increased development.
- WHO Severe Pneumonia [ Time Frame: Up to 12 months after birth ]WHO defines severe pneumonia as the presence of at least one of the following: oxygen saturation less than 90%, central cyanosis, severe respiratory distress, inability to drink breastfeed or vomiting everything, altered consciousness, and convulsions. Inpatient antibiotic treatment is recommended. The number of cases of severe pneumonia, according to WHO criteria, will be recorded.
- Brachial artery reactivity testing (BART) [ Time Frame: 18 months ]Brachial artery reactivity testing (BART) measures endothelial function via flow-mediated dilatation to reactive hyperemia following the release of arm blood-flow occlusion. In this test, baseline artery diameter is measured, then a blood pressure cuff is inflated to induce distal arm ischemia for 5 minutes and after releasing the pressure, the post-occlusion brachial artery diameter is measured. The ratio of post- to pre-occlusion artery diameter represents endothelial function where lower values indicate worse endothelial function.
- Carotid intima-media thickness (CIMT) [ Time Frame: 18 months ]The carotid intima-media thickness test (CIMT) is used to determine the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery and can detect plaque build up prior to physical symptoms being experienced. The carotid ultrasound will be performed with a portable ultrasound by trained sonographers.
- Adult respiratory health and well-being [ Time Frame: 18 months ]Adult respiratory health and well-being will be assessed with the St. George Respiratory Questionnaire (SGRQ). The SGRQ measures impaired health and perceived well-being among individuals with chronic airway disease. The SGRQ has sections assessing symptoms, activities that cause breathlessness or are limited because of breathlessness, and the impacts of respiratory problems on employment, sense of control of health, panic, stigmatization, medication use, side effects of therapies, expectations for health and disturbances of daily life. The questionnaire includes multiple choice, true/false and open-ended questions.
- Short Form 36 survey [ Time Frame: 18 months ]The Short Form 36 survey (SF-36) is a 36 item questionnaire evaluating quality of life. The survey has 8 sections (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health). Possible scores range from 0 (maximum disability) to 100 (no disability).
- Change in fine particulate matter (PM2.5) exposure [ Time Frame: Up to 12 months after delivery ]Personal monitoring equipment will be used to assess exposure to fine particulate matter (PM2.5) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation. Additionally, PH2.5 in the home will be measured 6 months and 12 months after delivery of the child.
- Carbon monoxide (CO) exposure [ Time Frame: Up to 12 months after delivery ]Personal monitoring equipment will be used to assess exposure to carbon monoxide (CO) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation. Additionally, CO in the home will be measured 6 months and 12 months after delivery of the child.
- Black carbon (BC) exposure [ Time Frame: Up to 12 months after delivery ]Personal monitoring equipment will be used to assess exposure to black carbon (BC) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation. Additionally, BC in the home will be measured 6 months and 12 months after delivery of the child.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02944682
|Contact: Thomas Clasen, PhDemail@example.com|
|Universidad del Valle de Guatemala||Recruiting|
|Guatemala, Guatemala, 01015|
|Contact: John McCracken +502 23298492|
|Sri Ramachandra University||Recruiting|
|Chennai, Tamil Nadu, India, 600116|
|Contact: Kalpana Balakrishnan 91-44-2476-7008|
|Puno Global Non-Communicable Disease Research Site, School of Medicine, Johns Hopkins University||Recruiting|
|Contact: William Checkley 443-287-8741|
|Rwanda Research Site, London School of Hygiene and Tropical Medicine||Recruiting|
|Contact: Maria Abadie Rosa +44 207 927 2686|
|Principal Investigator:||Thomas Clasen, PhD||Emory University|
|Principal Investigator:||Jennifer Peel, PhD||Colorado State University|
|Principal Investigator:||William Checkley, MD PhD||Johns Hopkins School of Medicine|